J. Clin. Chem. Clin. Biochem.
Vol. 19, 1981, pp. 81–87

Specific Quantitation by HPLC of Protein (Lysine) Bound Glucose in Human Serum Albumin and Other Glycosylated Proteins

By E. Schleicher and O. H. Wieland

Klinisch-chemisches Institut und Forschergruppe Diabetes, Städtisches Krankenhaus München-Schwabing

(Received March 31/July 28, 1980)

Summary: A specific and sensitive method for quantification of the fructose-lysine linkages present in non-enzymatically glycosylated albumin and other proteins is described. Protein is hydrolyzed for 18 h in 6 mol/l HCl at 95 °C to yield furosine (ϵ -N-(2-furoylmethyl)-L-lysine) known as a specific degradation product of fructose-lysine. Furosine is then separated on HPLC and quantified by its UV-absorbance against a prepared fructose-lysine standard. The method has been successfully used for the determination of glycosyl-albumin in diabetic patients starting from 100 μ l serum or less, as well as for various other proteins. Unlike the usually employed thiobarbituric acid assay the present procedure is truly specific for the detection of ketoamine linkages of glycosylated proteins.

Spezifische Bestimmung von Protein (Lysin)-gebundener Glucose in Serumalbumin des Menschen und anderen glycosylierten Proteinen durch Hochdruckflüssigchromatographie

Zusammenfassung: Es wird eine spezifische und empfindliche Methode zur Bestimmung der Fructose-Lysinbindungen von nichtenzymatisch glycosyliertem Albumin und anderen Proteinen beschrieben. Sie beruht auf der Hydrolyse des Proteins für 18 Stunden in 6 mol/l HCl bei 95 °C, wobei als spezifisches Abbauprodukt des Fructose-Lysins Furosine (ϵ -N-(2-Furoylmethyl)-L-lysin) entsteht. Furosine wird dann durch HPLC abgetrennt und durch UV-Absorption gegen einen selbstsynthetisierten Fructose-Lysinstandard gemessen. Die Methode eignet sich für die Bestimmung von glycosyliertem Albumin bei Diabetikern, ausgehend von 100 μ l Serum und weniger, sowie auch allgemein für das Studium glycosylierter Proteine. Sie ist spezifischer als der häufig gebrauchte Thiobarbitursäure-Test, indem sie ausschließlich die Ketoaminbindungen glycosylierter Proteine erfasst.

Introduction

The chemical reaction of reducing sugars with amino acids resulting in stable ketoamine adducts was first described by *Maillard* (1) and has since become a major investigational problem in food processing technology. With the discovery of a glucose adduct of haemoglobin (HbA_{1c}) in normal human erythrocytes (2) it became apparent that nonenzymatic attachment of sugars to amino groups of proteins does not only occur under artificial conditions, but also physiologically in the living organism. The later finding that there is an increase of this glycosylated haemoglobin in the erythrocytes of diabetic patients (3) has greatly stimulated further research in this field. More recently, serum albumin has been shown to undergo a similar reaction with glucose yielding a stable glycosylated form of albumin (4–10) which is also elevated in human diabetics (7–10) and in diabetic rats (6). These and other observations suggested the interesting possibility that

increased sugar adduction to macromolecules is a more generalized phenomenon in diabetes mellitus which may have pathophysiological implications in the development of diabetic microangiopathy and other late complications of the disease. The recent finding of glycosylation of the lens crystallins which alters their physical properties and has been implicated to be involved in diabetic cataract formation (11) appears of interest in this context. Further examples of nonenzymatic protein glycosylation are listed in table 1.

Chemically, the first reaction in the glycosylation of proteins is the formation of a *Schiff* base between the carbonyl group of an aldose or a ketose and the NH₂-group of an amino acid. The resulting aldimine linkage may then undergo isomerisation by the so called *Amadori* rearrangement (17) yielding the corresponding ketoamine compound. As the latter reaction seems hardly reversible under physiological conditions and so far no enzyme is known for the cleavage of the keto-

Tab. 1. Nonenzymatically glycosylated proteins.

Protein	Functional change	Ref.
Haemoglobin	Increased oxygen binding	3, 12
Lens crystallins	Loss of transparency	11
Insulin	Decrease in biological activity	13
Serum albumin	not known	4-10
Other serum proteins	not known	5, 7
Erythrocyte membrane protein	not known	14
Collagen (skin, aorta)	not known	15, 16

amino linkage, these adducts once formed show very great stability. A general reaction scheme is illustrated in figure 1.

The site of glucose adduction in the glycohaemoglobin fractions HbA_{1a,b,c} is the amino group of the terminal valine of the β -chains (18). Recent studies revealed that there is also glycosylation of the major haemoglobin fraction A₁₁ and that the glucose is bound here to ϵ -amino groups of lysine (19). Present available evidence suggests that the ϵ -amino groups of lysine residues and the N-terminal amino acids are a preferred locus for non-enzymatic attachment of hexoses to proteins.

The discovery by *Gottschalk* that N-substituted fructose-amines yield 5-hydroxymethylfurfuraldehyde upon mild acid treatment (2 mol/l acetic acid) (20) provided a clue for the detection of these compounds in natural products. A spectrophotometric method was then developed by *Keeney & Basette* (21) in their studies on the browning reaction in milk products using the 2-thiobarbituric acid reaction product of 5-hydroxymethylfurfuraldehyde after hydrolysis with oxalic acid. This assay was applied also for the determination of the glycosylated haemoglobins (22) and is now widely employed for the quantification of nonenzymatically glycosylated proteins.

Although the 2-thiobarbituric acid test is commonly considered specific for ketoamine linkages within glyco-

Fig. 1. General reaction scheme of the addition of glucose to an amino-group, showing formation of a *Schiff* base and the subsequent *Amadori* rearrangement which yields a stable ketoamine linkage.

sylated proteins it is not known whether and to what extent other types of carbohydrate linkages in glycoproteins contribute to 5-hydroxymethylfurfuraldehyde formation under these conditions. We were therefore interested in another procedure which might allow a more specific quantitation of ketoamine linkages in glycosylated body proteins. Again in dairy research it was observed that upon hydrolysis of industrial milk products an unknown lysine derivative is formed in appreciable amounts (~30%) (23). This was identified as the hydrolysis product of fructose-lysine, ϵ -N-(2-furoylmethyl)-L-lysine, called furosine (24, 25). The hydrolysate also contained about 10% of another product, ϵ -(3-hydroxy-4-oxo-6-methyl-1-pyridinyl)-L-norleucine, called pyridosine (26) (fig. 2). In the present work we report a sensitive and specific method for the determination of glycosylated albumin in human serum which is based on the formation of furosine after hydrolysis of purified albumin in 6 mol/l HCl. Furosine (and pyridosine) is then determined by HPLC. This method is applicable quite generally for the quantitative determination of fructose-lysine linkages in proteins and may therefore deserve special interest for future research into the possible significance of protein glycosylation, in particular with respect to the pathogenesis of the diabetic late complications.

Fig. 2. 6 mol/l HCl hydrolysis of ϵ -D-fructose-lysine gives rise essentially to the three products: lysine, furosine and pyridosine. Yields shown in brackets (According to I.c. (27)).

Materials and Methods

Chemicals

Lyophilized human albumin, reagent grade was purchased from Behring Corp., Marburg, GFR. Cellogel blocks from Chemetron, Milano, Italy were obtained via Serva, Heidelberg, GFR cat. no. 44225. The globulin fractions from human serum, α , β and γ corresponding to *Cohn*-fraction IV, III and II respectively, were also from Serva Heidelberg. D-[U-¹⁴C]glucose was purchased from the Radiochemical Centre Amersham, Braunschweig, GFR. NCS Tissue Solubilizer was from Amersham/Searle, Heusenstamm-TLC-plates (20 x 20 cm silicagel, 0.25 mm thick), Na-

Veronal, Veronal and all other standard laboratory reagents were from Merck, Darmstadt, GFR.

Fructose-lysine was prepared essentially according to *Brandt* (27). Prior to glucosylation, the α -amino group of lysine was protected by formylation according to *Hofman* (28). 400 mg N-formyl-lysine recrystallized from absolute ethanol and 5 g glucose were refluxed 8 hours in 100 ml absolute methanol at 60 °C and the solvent removed by vacuum distillation. To remove the formyl group, the residue was dissolved in 10 ml 1 mol/l HCl and heated for 15 min on a boiling water bath. The slightly brown product was applied to a column (15 × 1.5 cm) filled with Dowex 15 W × 8 (200–400 mesh), washed with 50 ml H₂O and eluted with 0.5 mol/l pyridinium acetate pH = 4.35. Fractions of 2 ml each were collected. To detect the fructose-lysine, samples from each fraction were spotted on a TLC-plate and developed in butanol: acetic acid: water = 80 ml + 20 ml + 20 ml. The amino acids were visualized by ninhydrin. The R_F -values for lysine and fructose-lysine were 0.05 and 0.10, respectively. The fractions 12–14, containing only fructose-lysine, were combined and lyophilized. The yield was 17%. A reference sample of fructose-lysine, a gift from Prof. *Erbersdobler*, Institut für Physiologie, physiologische Chemie und Ernährungsphysiologie, Fachbereich Tiermedizin, Universität München, migrated with the same R_F -value.

Chromatographic system

We used a model 6000A Solvent Delivery System, Model U6K Universal Injector and Model 440 Absorbance Detector (all from Waters Associates, Inc. Milford, MA 01757). The pre-packed column was a 30 cm × 3.9 mm "μBondapak C₁₈", average particle size 10 μm (Waters Associates, Inc.) and a 5 μm C₁₈-column (20 × 4 mm) from Macherey and Nagel (Düren, GFR). The eluents were filtered through a glass filter (pore size 0.5 μm; Millipore Corp., Bedford, MA 01730) and then degassed under reduced pressure for 30 minutes prior to use. Absorption was recorded simultaneously at 280 and 254 nm by arranging two cuvettes in tandem. Detector sensitivity was set at AUFS = 0.01. Peak heights at 280 and 254 nm were recorded on a 10 mV potentiometric dual channel chart recorder. 5–20 μl samples were injected and developed with 7 mmol/l H₃PO₄ on a μBondapak C₁₈-column at a flow rate of 1 ml/min (System A). For the 5 μm C₁₈-column the eluent was 5.6 mmol/l H₃PO₄ (System B). At a chart speed of 0.5 cm/min furosine eluted as a sharp peak after 3–4 min, tyrosine after ca. 9 min, and phenylalanine after ca. 14 min. All separations were performed at room temperature.

Standard solution

29.25 μmol fructose-lysine was dissolved in 10 ml 6 mol/l HCl and hydrolyzed for 18 hours at 95 °C (Eppendorf thermoblock). After evaporation of the HCl in vacuo the residue was dissolved in 1 ml H₂O, and 5–25 μl were applied to the HPLC (System B).

Isolation of human serum albumin by preparative electrophoresis has been described elsewhere (8). The albumin preparations were checked by immunoelectrophoresis (29) and shown to contain only traces, if any, of contaminating proteins. Protein was determined according to *Bradford* (30).

In vitro incorporation of D-[U-¹⁴C]glucose into human serum albumin

10 ml of a solution of 250 mg D-[U-¹⁴C]glucose containing 3.03 GBq/mol was added to 150 mg purified human albumin dissolved in 90 ml *Earle's* medium (31). After adjusting the pH to 7.5 by gassing with 95% O₂/5% CO₂, the mixture was incubated at 37 °C. 10 mg NaN₃ was added to prevent growth of microorganisms. Glucose incorporation was followed by mixing 25 ml samples with 5 ml 3 mol/l trichloroacetic acid, washing the precipitate twice with 0.6 mol/l trichloroacetic acid, and hydrolysis of the precipitate in 6 mol/l HCl as described previously. After injection of 20 μl of the hydrolysate for HPLC (System A) fractions were collected and counted for radioactivity in a Packard Tricarb Model 2660.

NaBH₄ reduction was carried out for 18 h at room temperature after adding 7 mg NaBH₄ to a solution of 15 mg human serum

albumin in 2 ml *Earle's* medium. The samples were precipitated with trichloroacetic acid and further treated with 6 mol/l HCl as described previously. All statistical data were computed with *Student's* t-test (32).

Results

Calibration curves and sensitivity

As illustrated in figure 3 there is a linear relationship between furosine formation (peak height) and varying concentrations of fructose-lysine used as standard. The appearance of the furosine peak on HPLC is shown on the insert of figure 3. To detect substances possibly interfering with the furosine peak we always recorded the ratio of the peak heights $A_{280\text{nm}}/A_{254\text{nm}}$ and found a constant value of 3.9 for furosine and of 1.2 for pyridosine.

Further proof that we determined only fructose-lysine was achieved by reducing human albumin with NaBH₄ prior to hydrolysis. Thereby the double bonds of the keto-group are reduced and no furosine and pyridosine could be found after hydrolysis.

Recovery of furosine was studied by adding fructose-lysine (29 and 58 nmol respectively) to 1 mg of human serum albumin (Behring) before hydrolysis. Another sample (29 nmol fructose-lysine) hydrolyzed without albumin served as standard. 79.9% of the added fructose-lysine was recovered as furosine in these experiments.

Stability

Serum samples stored at –20 °C showed no changes in the fructose-lysine content of the albumin up to 3 months.

Fig. 3. Standard curve of fructose-lysine analysed by HPLC as furosine and quantified from the height of the absorption peak at 280 nm. Insert: Chromatogram of 0.37 nmol fructose-lysine recorded at 254 and 280 nm absorbance. Conditions as described in Materials and Methods (HPLC-System B).

Precision

The precision of furosine determination was assessed on a human pool serum. The within run precision yielded a mean value of 0.722 nmol fructose-lysine/nmol albumin, coefficient of variation = 2.94%, ($n = 12$). The day to day precision from 20 determinations of the pool serum yielded a mean value of 0.715 nmol fructose-lysine/nmol albumin and a coefficient of variation of 8.4%.

In addition to furosine, tyrosine and phenylalanine can be measured by HPLC in the hydrolysates. The dependency of the peak heights $A_{280\text{nm}}$ and $A_{254\text{nm}}$ of tyrosine, furosine and phenylalanine on the amounts of albumin is illustrated in figure 4. Accordingly, either of the amino acids representative of the protein content of the sample can be used for internal standardisation.

In the experiments of table 2 in vitro glycosylation of purified human serum albumin was studied using ^{14}C -labelled glucose. As expected there was a time dependent increase of the amount of furosine determined by peak heights, and also of ^{14}C -radioactivity of the furosine fractions.

Fig. 4. Standard curve of human albumin: 7–60 nmol of electrophoretically purified serum albumin were hydrolysed as described and 5 μl of the hydrolysate were chromatographed on HPLC System B. Peak heights of phenylalanine ($\bullet$ — $\bullet$, $\lambda = 254\text{ nm}$), furosine ($\circ$ — $\circ$, $\lambda = 280\text{ nm}$) and tyrosine (Δ — Δ , $\lambda = 254\text{ nm}$; $\blacktriangle$ — $\blacktriangle$, $\lambda = 280\text{ nm}$) are shown.

Tab. 2. In vitro glycosylation of human serum albumin with D - $[^{14}\text{C-U}]$ glucose. 150 mg albumin were incubated for the times indicated. For further details see Materials and Methods. The value of furosine/tyrosine at zero time is due to endogenous fructose-lysine in the albumin preparation. cpm = counts/min

Incubation time (hours)	^{14}C -Glucose cpm/mg albumin	ratio furosine/tyrosine
0	—	0.37
4	473	0.42
6	632	0.44
24	1203	0.49
48	1496	0.54

Previous studies from this laboratory (7, 8), confirmed by others (10), have shown that there is a marked elevation of glycosylated albumin in the serum of diabetic patients as compared to non diabetic subjects. In these studies glycosylated albumin was determined spectrophotometrically by the condensation product of hydroxymethylfurfural with thiobarbituric acid as outlined in the introduction. As illustrated in figure 5 the elevation of glycosyl-albumin in diabetes can also be demonstrated by means of furosine determination. If one compares the HPLC pattern of albumin of a normal serum (fig. 5A) and of albumin of a diabetic patient (fig. 5B) there is a large increase of the furosine peak in the latter. Quantitatively this corresponds to 0.28 and 0.57 mol fructose-lysine per mol albumin in the normal and the diabetic serum, respectively.

Specificity of the furosine assay for sugar ketoamine linkages

Our NaBH_4 experiments provided strong evidence that furosine formation depends essentially upon the existence of the sugar ketoamine configuration of glycosylated albumin. In order to examine whether this also holds for other proteins (glycoproteins), which contain the major part of the carbohydrate not in ketoamine-linked form, we have subjected a variety of serum protein fractions to NaBH_4 reduction prior to furosine determination. In these studies we

Fig. 5. Chromatograms of two hydrolysed human serum albumins purified by celloblock electrophoresis. A: normal person, B: diabetic patient. Chromatography on HPLC system B.

have also measured in parallel the formation of 5-hydroxymethylfurfuraldehyde which is generally assumed to be specific for the quantitation of ketoamine linkages in glycosylated proteins. The results are summarized in table 3. From both the furosine and 5-hydroxymethylfurfuraldehyde data of the non-reduced, native proteins it is clear that not only albumin but also the other serum proteins – in particular the α -globulins – contain sugar in ketoamine form. This confirms earlier observations (5, 7). After reduction furosine is below the detection limits of the method, even in the carbohydrate-rich serum globulins including purified transferrin with a total carbohydrate content of 5.9% (33). In contrast, quite appreciable amounts of 5-hydroxymethylfurfuraldehyde were still demonstrable after NaBH_4 treatment which must have come from nonreducible carbohydrate bonds of the glycoproteins. Thus the 5-hydroxymethylfurfuraldehyde assay appears only partially specific for the determination of ketoamine linked sugars and should therefore be used with precaution for studies of nonenzymatic protein glycosylation.

In these experiments we have determined 5-hydroxymethylfurfuraldehyde by two different methods, e.g. colorimetrically with thiobarbituric acid (42) or by UV absorption of 5-hydroxymethylfurfuraldehyde after separation on HPLC (8). The data agreed quite well in two cases, but much higher values were obtained with the 2-thiobarbituric acid test for the other proteins (tab. 3). This also applies for whole serum where the 2-thiobarbituric acid test still yielded some 50% of 5-hydroxymethylfurfuraldehyde after reduction with

NaBH_4 , whereas furosine was below detection level (data not shown). We believe that the 2-thiobarbituric acid test is less reliable due to the very high blank values which are eventually obtained after hydrolysis. As table 3 further shows, the recovery of 5-hydroxymethylfurfuraldehyde from glycosylated proteins is much lower than that of furosine. Taking the 5-hydroxymethylfurfuraldehyde values determined by HPLC, they are roughly ten times lower than the fructose-lysine values both expressed as nmol/mg protein.

Discussion

Further research on non-enzymatic glycosylation of proteins depends to a great extent on the development of analytical procedures for specific and sensitive quantification of glycosylated proteins. In the case of HbA_{1a-c} the attachment of glucose to the amino groups of valine of the β -chains alters the charge of the molecules in such a way that they can be easily separated by ion exchange chromatography or by isoelectric focusing (34). Although very useful for routine work these methods cannot be considered sufficiently specific; for instance, on column chromatography HbF emerges at the same position as HbA_{1c} (35). The possibility of an immunological approach to the quantification of glycosylated proteins is suggested by the report of antibodies for HbA_{1c} determination (36).

Other procedures for measurement of glycosylated proteins are based on the chemical properties of the keto-

Tab. 3. Comparison of the furosine and the 5-hydroxymethylfurfuraldehyde method.

The proteins (about 6 mg) were dissolved in 2 ml 0.01 mol/l K-phosphate buffer pH = 7.8 containing 9 g/l NaCl. 1 ml of the samples was reduced by adding 20 mg NaBH_4 and keeping the samples for 3 h at room temperature and for a further 3 h at 4 °C. After dividing the samples in two parts the protein was precipitated with 0.2 ml 3 mol/l trichloroacetic acid and washed twice with 0.6 mol/l trichloroacetic acid.

For furosine analysis the trichloroacetic acid precipitate was suspended in 1 ml 6 mol/l HCl, hydrolysed and analysed as described in the methods section. For 5-hydroxymethylfurfuraldehyde analysis the trichloroacetic acid precipitate was suspended in 1 ml 9 g/l NaCl, and after addition of 0.5 ml 1 mol/l oxalic acid (42) heated for 4.5 hours on a boiling water bath. 5-hydroxymethylfurfuraldehyde was determined both by the thiobarbituric acid method (21), and by HPLC (8).

A = before reduction; B = after reduction.

	Furosine, nmol/mg protein			5-Hydroxymethylfurfuraldehyde, nmol/mg protein					
				HPLC method			2-Thiobarbituric acid method		
	A	B	$\frac{B \times 100}{A}$	A	B	$\frac{B \times 100}{A}$	A	B	$\frac{B \times 100}{A}$
Human albumin (Behring)	3.4	< 0.3	< 9	0.34	< 0.02	< 6	0.46	< 0.05	< 11
α -Globulin (Cohn-fraction IV)	5.6	< 0.3	< 5	0.46	0.11	24	0.55	0.37	67
β -Globulin (Cohn-fraction III)	1.45	< 0.3	< 20	0.14	0.09	64	0.29	0.25	86
γ -Globulin (Cohn-fraction II)	2.13	< 0.3	< 14	0.20	0.05	25	0.19	0.09	47
Transferrin	4.5	< 0.3	< 7	0.25	0.14	56	0.61	0.43	70

amine linkages, which result from nonenzymatic *Schiff* base formation and subsequent *Amadori* rearrangement. As already detailed in the introduction, sugar is released upon mild acid hydrolysis of the proteins in the form of 5-hydroxymethylfurfural, which can then be determined spectrophotometrically with thiobarbituric acid. This assay is widely used and considered to be specific for nonenzymatically glycosylated proteins. This is however true only for proteins having all their carbohydrate attached via ketoamine linkages, like the glycosylated haemoglobins or glycosylated serum albumin. From our data (tab. 3) it is however clear that glycoproteins whose glycosidic linkages are not reducible with NaBH_4 may contribute to 5-hydroxymethylfurfuraldehyde formation under the conditions of acid hydrolysis. NaBH_4 -treated controls are therefore always necessary when the 5-hydroxymethylfurfuraldehyde assay is used for the detection of ketoamine linked sugars in proteins.

It should further be noted that the thiobarbituric acid reaction also yields coloured products with compounds other than 5-hydroxymethylfurfuraldehyde (21, 37–40), which might possibly interfere with the spectrophotometric assay. The latter problem can be avoided by measuring 5-hydroxymethylfurfuraldehyde by its absorption at 280 nm after separation on HPLC (8).

From the foregoing it is clear that the 2-thiobarbituric acid test, though useful for routine analysis of glycosylated haemoglobin and albumin, has limitations if applied for the detection and quantitation of ketoamine linkages of glycoproteins in general. For this purpose the determination of furosine as described here appears to be more suitable, because furosine

is only formed from fructose-lysine linkages of proteins upon hydrolysis (24, 25). Thus one can obtain specific and quantitative information on the amount of glucose bound to ϵ -amino groups of lysine, the predominant sites for nonenzymatic glucose attachment to proteins. It should be noted that conjugates of glucose with other (terminal) amino groups also yield furosine-like degradation products upon hydrolysis in 6 mol/l HCl (24), which can be separated and measured by HPLC. Using fructose-valine (prepared according to l.c. (41)) as a standard, we have thus quantified the valine bound glucose in HbA_{1c} (data not shown). Other fructose amino acids which may occur in proteins can equally be determined if the corresponding standards are available.

Apart from its specificity the furosine assay is superior to the assay with 2-thiobarbituric acid with respect to sensitivity. This appears to be of special importance for the detection of nonenzymatically glycosylated proteins which may be obtained in only small amounts from tissues or cells. Thus by measuring furosine, we have been able to demonstrate the occurrence of fructose-lysine in glomerular basement membranes, erythrocyte membranes and plasma membranes of liver cells starting from a few milligrams of the purified preparations (unpublished results).

Acknowledgement

This work was supported by a grant of the Fritz-Thyssen Stiftung, Köln. The skillful technical assistance of Mr. Hubert Prokop is gratefully acknowledged.

References

- Maillard, L. C. (1912), *Compt. Rend. Hebd. Séance Acad. Sci.* 154, 66–68.
- Allen, D. W., Schroeder, W. B. & Balog, J. (1958), *J. Am. Chem. Soc.* 80, 1628–1634.
- Rahbar, S. (1968), *Clin. Chim. Acta* 22, 296–298.
- Bailey, A. J., Robins, S. P. & Tanner, M. J. A. (1976), *Biochim. Biophys. Acta* 434, 51–57.
- Day, J. F., Thorpe, R. & Baynes, J. W. (1979), *J. Biol. Chem.* 254, 595–597.
- Day, J. F., Thornburg, R. W., Thorpe, R. & Baynes, J. W. (1979), *J. Biol. Chem.* 254, 9394–9400.
- Dolhofer, R. & Wieland, O. H. (1979), *FEBS Lett.* 103, 282–286.
- Wieland, O. H., Dolhofer, R. & Schleicher, E. (1980), *Proc. 10th Congr. Intern. Diabetes Fed. (Waldhäusl, W. K., ed.)* pp. 721–727, Excerpta Medica, Amsterdam.
- Dolhofer, R. & Wieland, O. H. (1980), *Diabetes* 29, 417–422.
- Guthrow, C. E., Morris, M. A., Day, J. F., Thorpe, S. R. & Baynes, J. W. (1979), *Proc. Natl. Acad. Sci. U.S.A.* 76, 4258–4261.
- Stevens, V. J., Rouzer, C. A., Monnier, V. M. & Cerami, A. (1978), *Proc. Natl. Acad. Sci. U.S.A.* 75, 2918–2922.
- Bunn, H. F. & Briehl, R. W. (1970), *J. Clin. Invest.* 49, 1088–1095.
- Dolhofer, R. & Wieland, O. H. (1979), *FEBS Lett.* 100, 133–136.
- Weiss, J. B., Lote, C. J. & Bobinski (1971), *Nature New Biol.* 234, 25–26.
- Tanger, M. L., Fairweather, R. & Gallop, P. M. (1972), *Arch. Biochem. Biophys.* 151, 137–141.
- Rosenberg, H., Modrak, J. B., Hassing, J. M., Al-Turk, Walid A., & Stoks, S. J. (1979), *Biochem. Biophys. Res. Comm.* 91, 498–501.
- Hodge, J. E. & Rist, C. E. (1953), *J. Am. Chem. Soc.* 75, 316–322.
- Holmquist, W. R. & Schröder, W. A. (1966), *Biochemistry* 5, 2489–2504.
- Bunn, H. F., Shapiro, R., McManus, M., Garrick, L., McDonald, M., Gallop, P. M. & Gabbay, K. H. (1979), *J. Biol. Chem.* 254, 3892–3898.
- Gottschalk, A. (1952), *Biochem. J.* 52, 455–460.
- Keeney, M. & Basette, R. (1959), *J. Dairy Sci.* 42, 945–960.
- Flückiger, R. & Winterhalter, K. H. (1976), *FEBS Lett.* 71, 356–360.
- Erbersdobler, H. & Zucker, H. (1966), *Milchwissenschaft* 21, 564–568.
- Heyns, K., Heukeshoven, J. & Brose, K.-H. (1968), *Ange wandte Chemie* 15, 627–627.
- Finot, P. A., Bricout, J., Viani, R. & Mauron, J. (1968), *Experientia* 24, 1097–1099.

26. Finot, P. A. (1973), in: Protein human nutrition (Porter, J. W. G. & Rolls, B. A. eds.) p. 501, Academic Press, London-New York.
27. Brandt, Andrea (1978), Doctoral Thesis, University of Göttingen.
28. Hofmann, K., Stucz, E., Spühler, G., Yajima, H. & Schwartz, E. T. (1960), *J. Am. Chem. Soc.* **82**, 3727–3732.
29. Grabar, P. & Williams, C. A. (1953), *Biochim. Biophys. Acta* **10**, 193–194.
30. Bradford, M. M. (1976), *Anal. Biochem.* **72**, 248–254.
31. Altmann, P. L. & Dittmar, D. S. (1972), in: *Biology Data Book*, Vol. 1, p. 446, FASEB, Bethesda, Md. USA.
32. In: *Documenta Geigy, Wissenschaftliche Tabellen* (J. R. Geigy ed.) Basel, 1960, pp. 167–169.
33. In: *Molecular Biology of Human Proteins* (1966), (Schultze, H. E. & Heremans, J. F., eds.) Vol. 1, p. 212, Elsevier Publishing Company, Amsterdam, London, New York.
34. Schoos, R., Schoos, B. & Lambotte, C. (1978), *Clin. Chim. Acta* **86**, 61–65.
35. Dolhofer, R., Städele, A. & Wieland, O. H. (1977), *Klin. Wochenschr.* **55**, 945–954.
36. Javid, J., Pettis, R. K., Koenig, R. J. & Cerami, A. (1977), *Blood* **50** (suppl. 1) 110–110.
37. Baumgartner, W. A., Baker, N., Hill, V. A. & Wright, E. T. (1975), *Lipids* **10**, 309–311.
38. Warren, L. (1959), *J. Biol. Chem.* **234**, 1971–1975.
39. Waravdekar, V. S. & Saslaw, L. D. (1959), *J. Biol. Chem.* **234**, 1945–1950.
40. Kuwakara, S. S. (1980), *Anal. Biochem.* **101**, 54–60.
41. Heyns, K. & Breuer, H. (1958), *Chem. Ber.* **91**, 2750–2762.
42. McFarland, K. F., Catalano, E. W., Day, J. F., Thorpe, R. S., & Baynes, J. W. (1979), *Diabetes* **28**, 1011–1014.

Prof. Dr. O. Wieland
Klin.-chem. Institut
Krankenhaus Schwabing
Kölner Platz 1
D-8000 München 40